Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 5, 2023
June 5, 2023
160dff53-faf3-4095-b37e-414e108646cf
Related Documents
Cover Letter Attachments for Controlled Correspondences and ANDA Submissions: Guidance for Industry
Guidance DocumentJune 5, 2023Center for Drug Evaluation and Research
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry
Guidance DocumentJune 8, 2023Center for Drug Evaluation and Research
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry
Guidance DocumentJune 14, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.